CORE--DIAGNOSIS AND TREATMENT RESEARCH CORE

DTRC有三个主要目的：招募、诊断/评估和治疗。每个具体目标都有中心目标和核心目标，具体如下：招聘。为了确保MHCRC研究的充分和有效的受试者流动，我们计划集中我们现有的招聘工作。我们将招募范围广泛的精神分裂症和相关疾病患者，包括首发患者、急性加重的慢性患者、稳定的门诊患者、国家机构的慢性住院患者、有重大合并症的患者和无家可归者。此外，我们将继续从纽约州精神病学研究所（NYSPI）的正常对照组招募对照组，并为拟议的MHCRC提供有关该样本的最新诊断。2)。诊断/评估。我们将严格诊断和描述参与MHCRC研究方案的患者，并在精神病理学的多个领域（例如，与特征相关的症状、病程和神经认知变量）广泛取样精神分裂症相关疾病。核心特异性研究将建立在我们之前研究精神分裂症的无意识缺陷和自杀行为的工作基础上。3)。治疗。为入院的病人提供高质量的治疗-精神分裂症研究单位在Creedmoor （SRU- C）和精神分裂症研究单位在NYSPI (SRU- p)-和门诊研究和康复计划（ORR）。核心特异性治疗研究将特别侧重于对难治性患者使用非典型抗精神病药物。

The DTRC has three main aims: recruitment, diagnosis/assessment and treatment. Each specific aim has both center-wide and core-specific goals as follows: 1.) Recruitment. To ensure adequate and efficient subject flow for the MHCRC's studies we plan to centralize our existing recruitment efforts. We will recruit a broad range of patients with schizophrenia and related disorders including first-episode patients, chronic patients in acute exacerbation, stable outpatients, chronic inpatients in state facilities, patients with significant co-morbidities, and the homeless. In addition, we will continue to recruit controls from the Normal CONTROLS Unit at the New York State Psychiatric Institute (NYSPI) and to provide the proposed MHCRC with updated diagnoses on this sample. 2.) Diagnosis/Assessment. We will rigorously diagnose and characterize patients participating in the MHCRC's research protocols and broadly sample schizophrenia-related conditions across multiple domains of psychopathology (e.g. trait-related symptoms, course of illness, and neuro-cognitive variables). Core-specific research will build on our previous work studying unawareness deficits and suicidal behavior ion schizophrenia. 3.) Treatment. To provide high quality treatment to patients admitted to either inpatient site-the Schizophrenia Research Unit at Creedmoor (SRU- C) and the Schizophrenia Research Unit at NYSPI (SRU-P)- and the Outpatient Research and Rehabilitation Program (ORR). Core-specific treatment research will focus especially on the use of atypical antipsychotics with refractory patients.